Measuring cardiac troponins is integral to diagnosing acute myocardial infarction (AMI); however, troponins may be elevated without AMI, and the use of multiple different assays confounds comparisons. We considered characteristics and serial troponin values in emergency department chest pain patients with and without AMI to interpret troponin excursions. We compared serial troponin in 124 AMI and non-AMI patients from the observational Performance of Triage Cardiac Markers in the Clinical Setting (PEARL) study who presented with chest pain and had at least one troponin value exceeding the 99th percentile of normal. Because 8 assays were used during data collection, we employed a method of scaling the troponin value to the corresponding assay's 99th percentile upper reference limit to standardize the results. In 81 AMI patients, 96% had elevated troponin at the first test following initial elevation, compared to 73% of the 43 non-AMI patients ( P < 0.001). Scaling troponin to the 99th percentile of normal yielded a median value that was 4.8 [2.2, 14.1] times higher than the 99th percentile cutpoint among AMI patients, compared to 2.3 [1.5, 6.5] times higher among non-AMI patients ( P = 0.04). The rise in serial scaled troponin values distinguished the AMI patients. Scaling to the 99th percentile was useful for comparing troponin when different assays were utilized. H igh-sensitivity troponin I testing has been shown to improve the early diagnosis of acute myocardial infarction (AMI) and aid with risk stratifi cation ( 1 -3 ). Investigators using a registry in Australia and New Zealand determined that high-sensitivity troponin I testing was associated with fewer in-hospital adverse events for patients hospitalized with possible acute coronary syndrome ( 4 ) . Th ere are multiple non-AMI clinical scenarios, however, where troponin may exceed the 99th percentile, including renal failure, stroke, heart failure, pulmonary embolism, sepsis, and hypertension ( 5 ) . We capitalized on a data set of chest pain patients who had serial troponin assays performed, had at least one positive value, and had central adjudication of the outcome of AMI. We compared the characteristics, as well as the dynamic rise and fall of troponin, in this group of patients to better understand how to quantitatively evaluate the excursion of troponin and relate it to the confi rmed diagnosis of AMI.
METHODS
We performed retrospective analyses on data collected from a prospective, multicenter, observational study (Performance of Triage Cardiac Markers in the Clinical Setting [PEARL]) that examined the use of troponin for the diagnosis of AMI in patients ≥21 years of age who presented to the emergency department with symptoms of possible AMI from August 2014 through February 2015. Patients with symptoms including sharp or dull chest pain, tightness, sensations of heavy weight on the chest, pain in the jaw or neck, pain radiating down the arms, and dyspnea were monitored for approximately 24 hours. A team of 3 experienced adjudicators (1 emergency physician and 2 cardiologists) independently reviewed case report forms and the 12-lead electrocardiogram recorded during initial evaluation plus at least one additional electrocardiogram if obtained in the subject evaluation period to form a diagnosis of AMI or non-AMI using contemporary guideline defi nitions ( 6 ) . Discrepancies were discussed until consensus was reached. All institutions received institutional review board approval and patients' informed consent prior to conducting this study.
Troponin was evaluated using one of the following tests: Abbott ARCHITECT STAT TnI ( 7 ) , Abbott i-STAT ® POC cTnI ( 8 ) , Alere Triage ® POC cTnI ( 9 ), Beckman Coulter Access ® AccuTnI ® +3 ( 10 ), Ortho VITROS ® TnI ES ( 11 ), Roche Cobas ® TnT ( 12 ), Siemens ADVIA Centaur ® TnI-Ultra ( 13 ), or Siemens Dimension Vista ® TnI ( 14 ) . Th ese tests yielded results in diff erent measurable ranges with unique 99th percentile cutpoints. For that reason, we treated the data in two ways. First, we dichotomized the results as being either elevated or not elevated based on the 99th percentile cutoff rules for each assay. Second, to standardize the many troponin assays, we scaled the results using the ratio of the observed troponin value divided by the 99th percentile upper reference limit ("normal" value) ( 15 ) . For example, a patient with a troponin value of 0.1 ng/mL using the Roche Cobas ® TnT, which has a 99th percentile upper reference limit of 0.01 ng/mL, would have a scaled result of 0.1/0.01 = 10. We interpret this as a troponin value that is 10 times that of the 99th percentile of normal. We considered results from both methods across the sequence of troponin tests following the initial elevated result.
Continuous variables are reported as medians [quartile 1, quartile 3], and categorical variables are reported as frequencies (percent). Diff erences between diagnosis groups were tested using Fisher's exact test, 2-sample t test, or Wilcoxon rank sum test, as appropriate. All analyses were conducted using SAS 9.4, Cary, NC.
RESULTS
A total of 458 patients enrolled in the PEARL study from 8 facilities. Of the 458 patients, 20 withdrew during the observation period, leaving a total of 438 patients who received an adjudicated diagnosis. Th ere were 1179 total troponin values, 391 (33%) of which were greater than the corresponding 99th percentile upper reference limit. A total of 124 (28%) of the 438 patients had at least one elevated troponin level and are the focus of this article. Eighty-one (65%) of the 124 patients were adjudicated as AMI and the remaining 43 (35%) as non-AMI. Among these 124 patients, the AMI group was more likely to have previously known coronary artery disease than the non-AMI group (57% and 31%, respectively; P = 0.008). Conversely, the AMI group was less likely to have renal failure compared to the non-AMI group (5% and 35%, respectively; P < 0.001). Sample characteristics for the 124 patients with elevated troponin appear in Table 1 .
Th e median time from arrival to fi rst elevated troponin was 1.17 [0.70, 3.25] hours for AMI patients and 0.97 [0.60, 4.13] hours for non-AMI patients ( P = 0.08) ( Figure 1 ). Additionally, the median time between the fi rst elevated troponin and subsequent test was 3.79 [2.25, 6.77] hours for AMI patients and 3.80 [2.25, 5 .70] hours for non-AMI patients ( P = 0.81). Similarly, the median times between the fi rst and second test following the initial elevation, as well as the second and third test following the initial elevation, did not diff er ( P = 0.95 and 0.37, respectively). Th e median number of troponin tests performed per patient until the fi rst elevation occurred was 1 for both AMI and non-AMI patients; however, the median total number of tests performed for AMI patients was 4 [3, 5] , compared to 3 [2, 4] for non-AMI patients ( P = 0.01). Of the 124 patients who had at least one elevated troponin, 114 (91.9%) had at least one subsequent test performed. Among the 77 retested AMI patients, 74 (96.1%) were confi rmed to have elevated troponin on the following lab draw. In contrast, only 27 (73.0%) of the 37 retested non-AMI patients had an elevated result at the following test ( P < 0.001) ( Figure 2 ). After the fi rst elevated troponin, a diff erence in the rate of elevation was not observed between AMI and non-AMI patients on the second or third subsequent lab draws ( P = 0.60 and 0.31, respectively).
When considered as a continuous variable scaled to the 99th percentile upper reference limit, we observed a median troponin that was 4.8 [2.2, 14.1] times higher than the upper limit of normal among AMI patients, compared to a median 2.3 [1.5, 6.5] times higher than the upper limit of normal among non-AMI patients ( P = 0.04). Th e AMI group's median troponin during the fi rst test following the initial elevation was 10.2 [3.4, 73.3] times that of normal compared to 2.0 [0.9, 5.5] times that of normal for the non-AMI group ( P < 0.001). Further, the median paired diff erence between patients' initial elevated troponin and subsequent test was 4.1 [0.1, 39.7] for AMI patients and -0.2 [-1.6, 0.5] for non-AMI patients ( P < 0.001). Additionally, the median scaled troponin was 16.7 [4.3, 95.3] for AMI patients on the second lab draw following the initial elevated result, compared to 3.3 [2.0, 16.7] for non-AMI patients ( P = 0.002). Finally, the median scaled troponin was 18.8 [4.0, 49.6] for AMI patients on the third lab draw following the initial elevation compared to 4.6 [2.1, 18.6] for non-AMI patients ( P = 0.03). To verify that these fi ndings were not driven by an uneven utilization of assays between AMI and non-AMI patients, we conducted chi-square tests and confi rmed that there were no signifi cant diff erences between the groups' assays at any of the four lab draws analyzed ( P values = 0.30, 0.31, 0.44, 0.07). Th e diff erences and rates of change in median scaled troponin for AMI and non-AMI patients are shown in Figure 3 and Figure 4 , respectively.
DISCUSSION
Among 124 emergency department patients who presented with chest discomfort and at least one positive troponin value using contemporary sensitivity assays, 65.3% were confi rmed to have AMI by an independent adjudication panel. Ninety-six percent of the AMI patients had confi rmatory elevated troponins upon serial testing in the emergency department. Use of the 99th percentile cutpoint of normal and scaling of the elevation to that anchor provided clear diff erences in the excursions of troponin between those with and without AMI.
Our analyses provide a response to the criticisms regarding the high rate of false-positive cases generated as a result of considering the 99th percentile cutoff as positive or negative on single tests ( 16 , 17 ) . Considering the change in serial values of troponin concentration scaled to the 99th percentile has previously been shown as superior to the 99th percentile cutoff alone ( 18 ) . After performing these analyses, we also considered the diff erences in raw troponin values between AMI and non-AMI patients at the 4 timepoints and found that they were in agreement with the scaled results ( P = 0.006, <0.001, <0.0001, 0.04). Although using the raw and scaled values yielded similar statistical results, the conclusions drawn with the raw values were far more confounded due to the use of several assays, whereas the scaled values off ered a standardized interpretation, regardless of assay.
We found that the fi rst troponin test alone was not suffi ciently informative, nor was it elevated at an earlier time in those diagnosed as AMI or non-AMI. Th ere was a quantitative diff erence in the rate of troponin elevation at the fi rst test following initial elevation; however, a signifi cant diff erence in the rates of troponin elevation was not observed in the second and third subsequent draws following the initial elevation among AMI and non-AMI patients. Th is was likely attributed to the diff ering rates of clinically driven retesting within each group over time. For example, only 23 (53.5%) patients without an AMI were tested ≥2 times after the initial elevation, compared to 67 (82.7%) of those retested with an AMI. Th is was not surprising because AMI patients were more likely to have a history of coronary artery disease pointing to a higher clinical suspicion and a more assiduous approach to the diagnosis of AMI.
Although we did not observe signifi cant diff erences in dichotomized rates of troponin elevation at every lab draw, we did observe higher median scaled troponin values in AMI patients compared to non-AMI patients. As shown in Figure 3 , the gradient of the troponin line sharply increased for those with AMI, while the line for those without AMI was relatively fl at. Th is indicated that those with AMI had true ischemic rises, while those without AMI had slight elevations in troponin attributed to other causes. Th ese results confi rmed the fi ndings of a previous study, which suggested that the method of scaling troponin in terms of the 99th percentile is viable ( 19 ) . In another study, patients with asymptomatic AMI (as diagnosed via electrocardiogram) were shown to have higher median high-sensitivity troponin I values than patients who did not have an AMI ( 20 ) . Our results and those of others suggest that the interpretation of the excursion of serial troponin rather than single troponin values is critical in the diagnosis of AMI.
Th is work was a retrospective secondary analysis of an observational data cohort and is therefore subject to the inherent limitations of such studies. Th e study enrolled via convenience sample, so there is the potential for selection bias. We conducted analyses based on many diff erent contemporary troponin assays, including troponin I and troponin T across a variety of laboratory platforms. Th e multiplicity of testing was clinically determined and was clearly biased by the physician's suspicion of AMI. Troponin testing provides no information to distinguish between type 1 or type 2 myocardial infarction. Because this analysis considered only those patients with elevated troponin, our sample size was small, which limited the power and generalizability of the results. Finally, we recognize that our study results may not generalize to populations with greater comorbidities, including renal failure, sepsis, heart failure, and other illnesses, where there may be greater proportions of troponin elevation or greater diffi culty in determining AMI ( 21 -23 ) .
